New Delhi, May 14 (PTI) A national tracking platform will be established soon to determine the impact of the jabs against COVID-19 and the breakthrough infections that are likely to occur among those with complete and partial immunisation, official sources said.
The recommendation of the National Technical Advisory Group on Immunisation (NTAGI) to establish such a platform has been accepted by the National Expert Group on Vaccine Administration for COVID-19 and the Union Health Ministry, they said.
'The COVID-19 Working Group which is part of NTAGI has strongly recommended to urgently establish a national vaccine tracking platform to determine the impact of the COVID vaccine(s) and the breakthrough infections that are likely to occur among those with complete and partial immunisation,' said Dr N K Arora, the INCLEN Trust chairperson who heads the COVID-19 Working Group.
The vaccine tracker will be particularly important to monitor the impact of increasing the dosing schedule of Covishield, he said, as the government on Thursday accepted the working group's recommendation to extend the gap between the two doses of the Covishield vaccine from 6-8 weeks to 12-16 weeks.
The current data harmonisation work of the Indian Council of Medical Research (ICMR) and other agencies can be leveraged to set up this facility for review of ground realities on real-time basis, the NTAGI has recommended.
The government panel has also recommended that pregnant women may be offered the choice to take any of the COVID-19 vaccines and that lactating women can be inoculated any time after delivery.
The NTAGI has also stated that those having laboratory test proven SARS-CoV-2 illness should defer COVID-19 vaccination for six months after recovery, the sources said.
According to the health ministry's current protocol, vaccine is to be taken four to eight weeks after recovery from COVID-19 infection and pregnant and lactating women are not to be administered the shots.
The NTAGI recommended that all pregnant women visiting for antenatal care (ANC) may be informed about risks and benefits associated with Covishield and Covaxin. Based on the information provided, a pregnant woman may be offered the choice to take any of the vaccines.
An educational tool comprising information on risk of COVID-19 infection during pregnancy, benefits associated with the vaccination and rare complications associated with vaccines like thrombosis and thrombocytopenia (with Covishield) may be developed.
In case of individuals who have received the first dose and before completion of the dosing schedule if they test positive for COVID-19, they should wait for 4-8 weeks after clinical recovery from the illness.
Also, COVID-19 patients who have been given anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma may defer vaccination for three months from the day of discharge from hospital, the recommendations stated.
Individuals having any other serious illness requiring hospitalisation or ICU care should also wait for 4-8 weeks before getting the vaccine, it added. PTI PLB SMN SMN